IA
LUCD icon

IFP Advisors’s Lucid Diagnostics LUCD Stock Holding History

IFP Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43 Buy
37
+9
+32% +$11 ﹤0.01% 4848
2025
Q4 		$31 Sell
28
-355
-93% -$397 ﹤0.01% 4762
2025
Q3 		$387 Buy
+383
New +$418 ﹤0.01% 4249

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

IFP Advisors's LUCD Position: Q1 2026 in Review

IFP Advisors increased its Lucid Diagnostics (LUCD) stake by 32% in Q1 2026, buying an estimated $11 and bringing the position to 37 shares worth $43. The position accounts for ﹤0.01% of the portfolio, ranked #4848.

IFP Advisors first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. The position peaked at $387 in Q3 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • IFP Advisors held 37 shares of Lucid Diagnostics worth $43 as of Q1 2026.
  • IFP Advisors bought 9 Lucid Diagnostics shares in Q1 2026, an estimated $11.
  • Lucid Diagnostics made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #4848 holding.
  • IFP Advisors first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • IFP Advisors's Lucid Diagnostics position peaked at $387 in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.